Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy

American Journal of Gastroenterology

Volumn 101, Issue 10, 2006, Pages 2275-2282

  Homoncik, Monika ^a   Sieghart, Wolfgang ^a   Formann, Elisabeth ^a   Schmid, Monika ^a   Ferenci, Peter ^a   Gangl, Alfred ^a   Jilma, Bernd ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PROTEINASE ACTIVATED RECEPTOR 1; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BLOOD CELL COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; P-SELECTIN; POLYETHYLENE GLYCOLS; RECEPTOR, PAR-1; RIBAVIRIN; THROMBOCYTOPENIA;

EID: 33749176563     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00774.x     Document Type: Article

References (35)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
2. Fried MW, Peter J, Hoots K, et al. Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002;36:967-72.
3. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statement 2002;19:1-46.
4. Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20.
5. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-51.
6. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(suppl 1):S237-44.
8. Shrestha R, McKinley C, Bilir BM, et al. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995;90:1146-7.
9. López Morante AJ, Sáez-Royuela F, Casanova Valero F, et al. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C. Am J Gastroenterol 1992;87:809-10.
10. Pardo M, Marriott E, Moliner MC, et al. Risks and benefits of interferon-alpha in the treatment of hepatitis. Drug Saf 1995;13:304-16.
11. Dessypris E, Graber SE, Krantz SB, et al. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988;72:2060-2.
12. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
13. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
14. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
15. Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987;79:286-9.
16. Papayannopoulou T, Brice M, Farrer D, et al. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol 1996;24:660-9.
17. Tsukada J, Misago M, Kikuchi M, et al. The effect of high doses of recombinant human erythropoietin on megakaryocytopoiesis and platelet production in splenectomized mice. Br J Haematol 1990;76:260-8.
18. Berridge MV, Fraser JK, Carter JM, et al. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 1988;72:970-7.
19. Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992;42:668-72.
20. Pirisi M, Fabris C, Soardo G, et al. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994;21:376-80.
21. Homoncik M, Jilma-Stohlawetz P, Schmid M, et al. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004 15;20:437-43.
22. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-9.
23. van van Geet C, Hauglustaine D, Verresen L, et al. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989;61:117-21.
24. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
25. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-87.
26. Reiter R, Derhaschnig U, Spiel A, et al. Regulation of protease-activated receptor 1 (PAR-1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 2003;90:898-903.
27. Jilma-Stohlawetz P, Homoncik M, Jilma B, et al. High levels of reticulated platelets and thrombopoietin characterize fetal thrombopoiesis. Br J Haematol 2001;112:466-8.
28. Homoncik M, Blann AD, Hollenstein U, et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000;111:1250-2.
29. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-21.
30. Homoncik M, Ferlitsch A, Ferenci P, et al. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005;21:49-55.
31. Wolf RF, Gilmore LS, Friese P, et al. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost 1997;77:1020-4.
32. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995;85:1719-26.
33. Stohlawetz P, Horvath M, Pernerstorfer T, et al. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion 1999;39:506-14.
34. Shore-Lesserson A, Tameshwar A, Marietta DePerio RN, et al. Platelet-activated clotting time does not measure platelet reactivity during cardiac surgery. Anesthesiology 1999;91:362-8.
35. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998;65:352-8.